

28 November 2018

CLEANSING STATEMENT

Ultima United Limited (ASX: UUL – the "Company" or "Ultima") has issued and allotted 3,825,097 ordinary shares at an issue price of \$0.10 per share to sophisticated investors. Below is the applicable Cleansing Notice.

Secondary Trading Exemption:

The Act restricts the on-sale of securities issued without disclosure, unless the sale is exempt under Section 708 or 708A. By the Company giving this notice, a sale of the Securities noted above will fall within the exemption in section 708A(5) of the Act.

The Company hereby notifies the ASX under paragraph 708(A)(5)(e) of the Act that:

- a) The Company issued the Securities without disclosure to investors under Part
 6D.2 of the Act;
- b) As at the date of this notice the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company, and section 674 of the Act; and
- c) As at the date of this notice there is no information:
 - i) that has been excluded from a continuous disclosure notice in accordance with the Listing Rules; and
 - ii) that investors and their professional advisors would reasonably require for the purpose of making an informed assessment of:
 - (1) The assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
 - (2) The rights and liabilities attaching to the Securities.

Yours sincerely

Piers Lewis Company Secretary

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Ultima United Limited

ACN

123 920 990

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

Class of +securities issued or to be issued

Fully paid ordinary shares

- 2 Number of *securities issued or to be issued (if known) or maximum number which may be issued
- 3 Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)

3,825,097

Fully paid ordinary shares ("Shares")

⁺ See chapter 19 for defined terms.

4 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

-) the date from which they do
-) the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
-) the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 5 Issue price or consideration
- 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)

Capital raising to sophisticated investors for working capital purposes as announced on 15 November 2018.

6a Is the entity an ⁺eligible entity that has obtained security holder approval under rule 7.1A?

> If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i

- 6b The date the security holder resolution under rule 7.1A was passed
- 6c Number of +securities issued without security holder approval under rule 7.1
- 6d Number of *securities issued with security holder approval under rule 7.1A

23 November 2018

3,825,097

\$0.10

Yes

Nil

⁺ See chapter 19 for defined terms.

- 6e Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
- 6f Number of +securities issued under an exception in rule 7.2
- 6g If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.
- 6h If ⁺securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements
- 7 ⁺Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

8 Number and ⁺class of all ⁺securities quoted on ASX (*including* the ⁺securities in section 2 if applicable)

Number	+Class
29,325,749	Fully Paid Ordinary Shares

d Nil

N/A

N/A

7.1 – 1 7.1A – 2,550,065

28 November 2018

+ See chapter 19 for defined terms.

- 9 Number and ⁺class of all ⁺securities not quoted on ASX (*including* the ⁺securities in section 2 if applicable)
- 10 Dividend policy (in the case of a Trust, distribution policy) on the increased capital (interests)

Is security holder approval N/A

Part 2 - Pro rata issue

11

	required?	
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the ⁺ securities will be offered	N/A
14	⁺ Class of ⁺ securities to which the offer relates	N/A
15	⁺ Record date to determine entitlements	N/A
16	Will holdings on different	N/A
	registers (or subregisters) be aggregated for calculating	
	entitlements?	
17	Policy for deciding entitlements	N/A
	in relation to fractions	
.0	Names of countries in which the	
18	Names of countries in which the entity has security holders who	N/A
	will not be sent new offer	
	documents	
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of	N/A
	acceptances or renunciations	
20	Names of any underwriters	N/A
_0	i and i any and i writers	11/11
21	Amount of any underwriting fee	N/A
	or commission	
+ See ch	hapter 19 for defined terms.	

- Names of any brokers to the N/A 22 issue
- Fee or commission payable to the 23 broker to the issue
- Amount of any handling fee 24 payable to brokers who lodge acceptances or renunciations on behalf of security holders
- If the issue is contingent on 25 security holders' approval, the date of the meeting
- Date entitlement and acceptance 26 form and offer documents will be sent to persons entitled
- If the entity has issued options, 27 and the terms entitle option holders participate to on exercise, the date on which notices will be sent to option holders
- Date rights trading will begin (if | N/A 28 applicable)
- Date rights trading will end (if 29 applicable)
- How do security holders sell 30 their entitlements in full through a broker?
- How do security holders sell *part* 31 of their entitlements through a broker and accept for the balance?

N/A			
N/A			

N/A

How do security holders dispose	N/A
of their entitlements (except by	
sale through a broker)?	

⁺Issue date N/A 33

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

32

N/A

N/A

N/A

N/A

N/A

04/03/2013

⁺ See chapter 19 for defined terms.

- 34 Type of ⁺securities (*tick one*)
- (a) +Securities described in Part 1
- (b)

All other *securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

- 35 If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
- 36 If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories 1 - 1,000

1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over

37

A copy of any trust deed for the additional ⁺securities

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

- 38 Number of *securities for which *quotation is sought
- 39 ⁺Class of ⁺securities for which quotation is sought
- 40 Do the ⁺securities rank equally in all respects from the ⁺issue date with an existing ⁺class of quoted ⁺securities?

If the additional ⁺securities do not rank equally, please state:

-) the date from which they do
-) the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
-) the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another ⁺security, clearly identify that other ⁺security)

42 Number and ⁺class of all ⁺securities quoted on ASX (*including* the ⁺securities in clause 38)

Number	+Class

⁺ See chapter 19 for defined terms.

Quotation agreement

- ¹ ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 -) The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 -) There is no reason why those +securities should not be granted +quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
-) If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	Date: 28 November 2018
	(Director/Company secretary)

Print name: Piers Lewis

== == == == ==

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
<i>Insert</i> number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	25,500,652
 Add the following: Number of fully paid ⁺ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid ⁺ordinary securities issued in that 12 month period with shareholder approval Number of partly paid ⁺ordinary securities that became fully paid in that 12 month period Note: Include only ordinary securities here – 	Nil
 other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
<i>Subtract</i> the number of fully paid ⁺ ordinary securities cancelled during that 12 month period	Nil
	1

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"			
"B"	0.15		
	[Note: this value cannot be changed]		
<i>Multiply</i> "A" by 0.15	3,825,098		
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule		
<i>Insert</i> number of +equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	3,825,097		
• Under an exception in rule 7.2			
Under rule 7.1A			
• With security holder approval under rule 7.1 or rule 7.4			
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 			
"C"	1		
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1			
"A" x 0.15	3,825,098		
Note: number must be same as shown in Step 2			
Subtract "C"	3,825,097		
Note: number must be same as shown in Step 3			
<i>Total</i> ["A" x 0.15] – "C"	1 [Note: this is the remaining placement capacity under rule 7.1]		

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities Step 1: Calculate "A", the base figure from which the placement capacity is calculated			
			"A"
Note: number must be same as shown in Step 1 of Part 1			
Step 2: Calculate 10% of "A"			
"D"	0.10		
	Note: this value cannot be changed		
<i>Multiply</i> "A" by 0.10	2,550,065		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used			
<i>Insert</i> number of ⁺ equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Nil		
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 			
"E"	Nil		

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A

"A" x 0.10	2,550,065
Note: number must be same as shown in Step 2	
Subtract "E"	Nil
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	2,550,065
	Note: this is the remaining placement capacity under rule 7.1A